2nd Annual Neuropsychiatric Drug Development (NPD) Summit

2nd Annual Neuropsychiatric Drug Development (NPD) Summit is organized by Hanson Wade and will be held from Jul 23 - 25, 2019 at Wyndham Boston Beacon Hill, Boston, Massachusetts, United States of America.

Description:
With the huge unmet clinical need in neuropsychiatry and despite multiple approved pharmaceuticals available, the development of the next generation of neuropsychiatric drugs is essential.

Historically, drug development within neuropsychiatry has been stifled for decades by a lack of scientific progress in the neuropsychiatric field combined with costly and challenging clinical trials.

The abundance of excitement and scientific progress in the field – especially with the recent approval of esketamine – will be captured at the NPD summit, as well as unravelling the complexities of developing truly transformative neuropsychiatric drugs.

With 70+ of the field’s thought-leaders uniting from around the world, NPD summit will be your opportunity to not only gather the latest scientific insights but to discuss, in depth, the challenges that have been stifling the progress of neuropsychiatric drug development such as translatable models, biomarkers and looking to target neuropsychiatry symptomatically.

Book early to avoid disappointment.

About the Event:
Built with thought-leaders at Sage Therapeutics, Janssen and Lundbeck the 2nd Annual NPD meeting will unravel the complexities of developing truly clinically transformative neuropsychiatric drugs.

Dedicated to overcoming challenges in neuropsychiatric drug development, this comprehensive discussion and networking forum will cover:

• Reviewing the current clinical landscape to share learned lessons, predict potential success and identify future opportunities
• Determine what we can expect from neuropsychiatric preclinical models to better predict clinical efficacy
• Utilize what we know from the clinical to improve our use of translational strategies
• Discuss the potential for digital therapeutics to transform the success of efficacious pharmaceuticals
• Review symptomatic focused drug development to identify the benefits and impact future regulation
• Evaluate the potential for different neuropsychiatric targets by improving our understanding of neuropsychiatric biology
• Improving our understanding of the role of genetics in neuropsychiatry and debating the future of precision medicine for neuropsychiatric disorders

Pre-Conference Workshops

Workshop A: Tuesday July 23, 8:00am – 11:00am
Understanding the Role of Genetics in Neuropsychiatric Disorders

Workshop B: Tuesday July 23, 11:30am – 2:30pm
Reviewing the Potential for Precision Medicine in Neurological Diseases

Workshop C: Tuesday July 23, 3:00pm – 6:00pm
Mitigating Risk in CNS Clinical Trials

Speakers: Al Robichaud, Chief Scientific Officer, Sage Therapeutics, Andreas Meier, Senior Medical Director, Ophthalmology, Pain and New Indications, Biogen, Alan Schatzberg, Professor, Psychiatry and Behavioral Sciences, Stanford University, Bruce Kimmel, Chief Executive Officer, Vidrio Technologies, Christopher Missling, Chief Executive Officer, Anavex Life Sciences, Daniel Hoeppner, Associate Director, Astellas, Elise Robinson, Assistant Professor, Harvard University, Eric Schaeffer, Senior Director, Neuroscience Innovation, Johnson andJohnson, George Papakostas, Scientific Director, Massachusetts General Hospital, Gopi Shanker, Director, Head of Psychiatry, Novartis, James Cassella, Chief Development Officer, Concert Pharmaceuticals , Jason Uslaner, Executive Director, Neuroscience, Merck, Joris Van Dam, Executive Director, Head of Digital Therapeutics, Novartis, Kevin Sanders, Global Development Lead Autism, Roche, Laura Corradini, Deputy Global Head Business Development and Licensing, CNS, Boehringer Ingelheim, Sean Smith, Executive Director, Neuroscience Discovery, Merck, Seth Hopkins, Executive Director, Translational Medicine, Sunovion, Shil Patel, Vice President, Codiak BioSciences, Stevin Zorn, President and CEO, MindImmune Therapeutics Inc, Sylvain Celanire, Chief Executive Officer, PRAGMA Therapeutics

Time: 8:00 am - 4:30 pm